Alzheimer Europe’s May 2020newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.
Summaries of a few of our top stories appear below.
Our monthly newsletter has over 8,500 subscribers and we are always happy to receive their comments, or suggested news items to share in future issues.
We were very sad to learn of the passing of our dear friend and colleague, Krister Westerlund, who died suddenly from heart failure on 16 May 2020 at the age of 75.
Alzheimer Europe has joined with other European health and patient-focused NGOs to support the EU4Health campaign, which calls for health to be made an EU policy priority.
Alzheimer Europe’s 30th Annual Conference #30AEC, which was planned to take place in Bucharest, will now be a virtual conference, under the banner “Dementia in a changing world”.
The European Commission has set out its vision of the future EU Health Programme, following the announcement of EUR 9.4 billion of funding in its recent budget proposal.
The US Food and Drug Administration (FDA) has approved Lilly's flortaucipir tracer for injection prior to PET scans, used to assess Tau neurofibrillary tangles in the brains of people with suspected Alzheimer's disease (AD).
This newsletter received funding under an operating grant from the European Union’s Health Programme (2014-2020).
The content of this newsletter represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.